Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Does natalizumab have a role in the treatment of relapsing multiple sclerosis?

Nature Clinical Practice Neurology volume 2, pages 476–477 (2006)Cite this article

boxed-textPolman CH et al. (2006) A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 354: 899–910

Background

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Goodin DS et al. (2002) Disease modifying therapies in multiple sclerosis. Neurology 58: 169–178

    Article  CAS  Google Scholar 

  2. Rudick RA et al. (2006) Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 354: 911–923

    Article  CAS  Google Scholar 

  3. Yousry TA et al. (2006) Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med 354: 924–933

    Article  CAS  Google Scholar 

  4. Ransohoff RM (2005) Natalizumab and PML. Nat Neurosci 8: 1275

    Article  CAS  Google Scholar 

  5. Voltz R et al. (2004) Mitoxantrone therapy in multiple sclerosis and acute leukaemia: a case report out of 644 treated patients. Mult Scler 10: 472–474

    Article  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Martina Habeck, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. consultant in neurology in the Department of Neurology, Medical School Hannover, and a member of the Center for Systems Neuroscience in Hannover, Germany

    Martin Stangel

Authors
  1. Martin Stangel
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Martin Stangel.

Ethics declarations

Competing interests

The author has received lecture fees from Biogen Idec, Sanofi-Aventis, Schering and Serono, and research support from Schering.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Stangel, M. Does natalizumab have a role in the treatment of relapsing multiple sclerosis?. Nat Rev Neurol 2, 476–477 (2006). https://doi.org/10.1038/ncpneuro0286

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpneuro0286

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing